Could a common drug protect the brain from Alzheimer's?
NCT ID NCT05386914
First seen Mar 17, 2026
Summary
This early study tests whether sirolimus, an FDA-approved drug, can improve blood flow to the brain in healthy adults with a genetic risk for Alzheimer's disease. Researchers will use MRI scans to measure changes after 4 weeks of daily low-dose sirolimus. The study also explores how lung function relates to brain blood flow. It involves 205 cognitively normal adults aged 45-65.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Missouri-Columbia
Columbia, Missouri, 65212, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus
What this could lead to
If it works, this could point toward a way to improve brain blood flow in people at risk for Alzheimer's disease.
What could go wrong
This is a very early Phase 1 study with only 4 weeks of treatment. It is not designed to test whether sirolimus prevents or treats Alzheimer's, only whether it changes blood flow.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.